AOL Money & Finance

Analyst upgrades, downgrades and initiations: AMGN, CS, DB, LEN, MET, SNI, X ...

More

Analyst upgrades:

  • Jefferies upgraded Autodesk (NASDAQ: ADSK) to Buy from Hold after the firm's channel checks indicated the company's business is stabilizing. Jefferies raised its target on shares to $27 from $20.
  • Citigroup upgraded Veeco (NASDAQ: VECO) to Buy from Hold on expectations LED order momentum will continue and cost discipline will help margin leverage. Citi raised its target on shares to $24 from $8.
  • Deutsche Bank upgraded Domtar (NYSE: UFS) to Buy from Hold on expectations earnings will improve meaningfully over the next year. The firm keeps a $24 price target on the stock.
  • Varian (NASDAQ: VARI) was upgraded to Equal Weight from Underweight at Barclays.
  • Air Products (NYSE: APD) was upgraded to Overweight from Neutral at JPMorgan.
  • U.S. Steel (NYSE: X) was upgraded to Buy from Neutral at Goldman.

Analyst downgrades:

  • FBR Capital downgraded Deutsche Bank (NYSE: DB) to Market Perform from Outperform following the Q2 results as the firm sees limited upside for the remainder of the year.
  • Baird downgraded Woodward Governor (NASDAQ: WGOV) to Neutral from Outperform citing the suspension of MPC from participating in federal programs and its impact on revenues. The firm has a $23 target on the stock.
  • Citigroup downgraded Lennar (NYSE: LEN) to Hold from Buy on valuation following the recent rally and maintains a $12 price target on the stock.
  • MetLife (NYSE: MET) was downgraded to Neutral from Buy at BofA/Merrill.
  • Credit Suisse (NYSE: CS) was downgraded to Underperform from Market Perform at FBR Capital.
  • Perrigo (NASDAQ: PRGO) was downgraded to Neutral from Outperform at Credit Suisse.

Analyst initiations:

  • Merriman initiated Celgene (NASDAQ: CELG) with a Buy rating. The firm believes recent data from Revlimid pivotal trials should drive investor interest in Celgene and set a $60-$66 target on the stock.
  • Merriman also initiated Poniard Pharm (NASDAQ: PARD) with a Buy rating. The firm is positive on Poniard given its wholly-owned, late-stage asset picoplatin and set a $14-$16 target range on the stock.
  • Morgan Joseph thinks that Amgen's (NASDAQ: AMGN) recent announcement of positive results from its FREEDOM trial shows that the company is capable of generating blockbuster drugs. The firm thinks the company has a strong pipeline and assumed coverage with a Buy rating and $77 target.
  • TreeHouse Foods (NYSE: THS) was initiated with a Hold rating at KeyBanc.
  • Scripps Networks (NYSE: SNI) was initiated with a Buy rating and $38 target at Deutsche Bank.
  • Limelight Networks (NASDAQ: LLNW) was initiated with a Market Perform rating at JMP Securities.
Symbol Lookup
IndexesChangePrice
DJIA+30.6910,464.40
NASDAQ+6.872,176.05
S&P 500+4.981,110.63

Last updated: November 26, 2009: 02:37 PM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

TheFlyOnTheWall.com Headlines

BioHealth Investor Headlines

WalletPop Headlines

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance

WalletPop Headlines